Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 21, 2018 and accepted by EDGAR at May 21, 2018, 16:40 ET.
Management's discussion and analysis
As filed, 13,170 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of income. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2017, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.
Forward-Looking Statement Notice
This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.
This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.
All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.
Overview
We are considered to be a commercial stage company, following the commencement of sales of stem cell separation equipment and disposable kits used in our Caverstem procedure to treat ED in the fourth quarter of 2017. Our fiscal year end is December 31st. We have acquired the licensing rights for our Amniostem amniotic-based stem cell, purchased the patent for our ED and lower back pain treatments, and filed patent applications for our neurological treatments.
During the first three months of 2018, we issued $287,500 in convertible notes with net proceeds of $254,350 to accredited investors. In addition, we issued $42,500 in convertible notes for services rendered and a $60,000 convertible note in exchange for a $50,000 convertible note.
During the three month period ending March 31, 2018, we incurred interest expense of $191,308 arising from the third party notes of $756,811.
Plan of Operations
We commenced marketing stem cell concentration machines and disposable kits for the Caverstem ED treatment in the fourth quarter of 2017. For the next 12 months our plan of operations is to market our stem cell concentration machines and disposable kits, complete the UCLA/LABiomed clinical trial and partner with leading researchers on investigator-initiated trials to advance our neurological programs. We estimate the costs to complete the clinical trials will be approximately $400,000, excluding overhead and other costs associated with maintaining our company structure. As of March 31, 2018, we had approximately $102,000 cash on hand. With an estimated monthly cash burn rate of approximately $65,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least June 2018. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of stem cell centration machines and disposable kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts and compete our ED clinical trial. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “ Act ”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.
Results of Operations – For the Three Month Period Ended March 31, 2018 and 2017
Gross Revenue. We generated $9,600 gross revenue for the three month period ended March 31, 2018 in comparison with $0 for the comparable quarter a year ago.
Cost of Goods Sold. We generated $2,400 cost of goods sold for the three month period ended March 31, 2018 in comparison with $0 for the comparable quarter a year ago.
Gross Profit/(Loss). We generated $7,200 in gross profit for the three month period ended March 31, 2018 in comparison with $0 for the comparable quarter a year ago.
General and Administrative Expenses. General and administrative expenses for the three month period ended March 31, 2018, totaled $202,930, in comparison with $178,378, for the comparable quarter a year ago. The increase of $24,552, or 14% is primarily due to consulting services and marketing fees associated with debt issuances, public company reporting and commercialization of the Caverstem procedure.
Research and Development Expenses. Research and development expenses for the three month period ended March 31, 2018, totaled $3,200 in comparison with $59,831, for the comparable quarter a year ago. The decrease of $56,631, or 95% is primarily due to a decrease of $46,007 in clinical research expenses associated with the erectile dysfunction trial and a reduction of $10,624 in laboratory expenses.
Other Income / Expense. Other expense for the three month period ended March 31, 2018, totaled $7,382,364 in comparison with other expense of $2,505, for the comparable quarter a year ago. The increase of $7,379,859, or 294,605% is primarily due to an increase of $188,803 in interest expense, $154,284 loss on extinguishment of convertible notes, and an expense of $7,036,772 associated with the change in the fair value of derivative liabilities.
Net Loss. For the reasons stated above, our net loss for the three month period ended March 31, 2018 totaled $7,586,580 in comparison to $243,351, for the comparable quarter a year ago.
Liquidity and Capital Resources
Our principal source of liquidity has been funds received from the sale of our common stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by third parties and revenues generated from our Caverstem ED procedure. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.
Our only commitments for expenditures relate to the completion of the clinical study for the ED stem cell treatment and general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED treatment.
For the next 12 months our plan of operations is to market the stem cell separator and disposable kits associated with the Caverstem ED treatment and complete the UCLA/LABiomed clinical trial. We estimate the costs to complete the clinical trials will be approximately $400,000, excluding overhead and other costs associated with maintaining our company structure. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.
Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Cash Flows
Net Cash used in Operating Activities. We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $164,937 for the three month period ended March 31, 2018 in comparison to $223,749 for the comparable period a year ago, a decrease of $58,812 or 26%. The decrease in cash used in operations was primarily related to payments towards an outstanding balance of management fees payable to a related party.
Net Cash used in Investing Activities. There was no cash used in investing activities in the three month period ended March 31, 2018 and the comparable period a year ago.
Net Cash From Financing Activities. In the three month period ended March 31, 2018 we raised $254,350 through the issuance of convertible and non-convertible debt. In the three month period ended March 31, 2017, we raised $100,000 through the sale of common stock. The increase in cash flows from financing activities was primarily related to our need to obtain additional capital due marketing expenses associated with the commercialization of the Caverstem ED procedure, increases in capital markets marketing costs and increased legal and accounting fees associated with public company reporting and audit requirements.
Basis of Presentation / Going Concern
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2018, the Company had $102,310 of available cash and a working capital deficit of $8,109,483. For the three month period ended March 31, 2018, the Company had $9,600 in revenue, $7,200 in operating income and used net cash for operating activities of $164,937. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.
Controls and procedures
As filed, 1,418 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13(a)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in internal control over financial reporting
There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-01-01 to 2018-03-31 | $9.6k | us-gaap:Revenues |
| Cost of revenue | 3 months2018-01-01 to 2018-03-31 | $2.4k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2018-01-01 to 2018-03-31 | $7.2k | us-gaap:GrossProfit |
| Research and development | 3 months2018-01-01 to 2018-03-31 | $3.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-01-01 to 2018-03-31 | −$204.2k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-01-01 to 2018-03-31 | $191.3k | us-gaap:InterestExpense |
| Net income | 3 months2018-01-01 to 2018-03-31 | −$7.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-01-01 to 2018-03-31 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2018-01-01 to 2018-03-31 | −$164.9k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2018-03-31 | $102.3k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-03-31 | $111.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $291.3k | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $8.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-03-31 | $8.2m | us-gaap:Liabilities |
| Long-term debt | At period end2018-03-31 | $756.8k | us-gaap:LongTermDebt |
Source: SEC EDGAR, the filing index for accession 0001144204-18-030097. Last ingested by Listed: Nov 14, 2026, 19:08 ET. Listed shows no prices and gives no investment advice.